**1 Zika virus replicates in skeletal muscle contributing to peripheral viral
2 amplification prior to reach neural tissue.**

3 Daniel Gavino-Leopoldino¹, Camila Menezes Figueiredo¹, Letícia Gonçalves
4 Barcellos¹, Mariana Oliveira Lopes da Silva¹, Suzana Maria Bernardino Araújo²,
5 Rômulo Leão da Silva Neris¹, Laryssa Daniele Miranda¹, Leandro Ladislau³, Claudia
6 Farias Benjamim⁴, Andrea Thompson Da Poain⁵, Julia Rosauo Clarke², Claudia Pinto
7 Figueiredo² and Iranaia Assunção-Miranda^{1*}

8

- 9 1. Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de
10 Janeiro, Rio de Janeiro, Brazil;
- 11 2. Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro,
12 Brazil;
- 13 3. Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio
14 de Janeiro, Brazil;
- 15 4. Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de
16 Janeiro.
- 17 5. Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio
18 de Janeiro, Rio de Janeiro, Brazil.

19

20 *Corresponding author

21 E-mail: iranaiamiranda@micro.ufrj.br

22

23

24

25

26 **Abstract**

27 Zika virus (ZIKV) infections are still a worldwide concern due to the severity of
 28 neurological outcomes. ZIKV neurotropism is well characterized, but peripheral tissue
 29 could be sites of viral amplification, contributing to endothelial-barrier crossing and
 30 access to peripheral nerves. During acute and late phases of infection, ZIKV can be
 31 detected in several body fluids, eyes, testis and vagina. However, the importance of
 32 initial replication sites for the establishment of infection and viral spread remain
 33 unknown. Here we demonstrated that ZIKV replicates primarily in human muscle
 34 precursor cells, resulting in cell death and inhibition of myogenesis. ZIKV also
 35 replicates in fetal muscle after maternal transmission and in infected neonate mice,
 36 inducing lesions and inflammation. Muscle was an important site of viral amplification,
 37 sustaining higher peripheral viral loads than liver and spleen. In addition, ZIKV showed
 38 rapid and sustained replication kinetics in muscle even before replication in the neural
 39 tissues, persisting until 16 days post infection. Our results highlight the importance of
 40 muscle in ZIKV pathogenesis as a peripheral site of viral amplification which may
 41 contribute to ZIKV reaching neural structures.

42 **Keywords:** Zika virus replication; skeletal muscle cells; muscle inflammation; viral
 43 dissemination; pathogenesis.

44

45

46

47

48

49

50 **Author Summary**

51 Zika Virus (ZIKV) neurotropism and its deleterious effects on central nervous system
52 have been well characterized. But, investigations of the initial replication sites for the
53 establishment of infection and viral spread to neural tissues remain under explored.
54 Here we demonstrated that ZIKV replicates primarily in human skeletal muscle
55 precursor cells, resulting in cell death and disrupted myogenesis. ZIKV also replicates
56 in muscle of fetus and neonate mice inducing muscle damage and inflammation. Muscle
57 replication occurs before amplification in peripheral nerves and brain, contributing to
58 the increase of peripheral ZIKV load and dissemination. In addition, ZIKV RNA still
59 been detected in skeletal muscle at late stages of infection. Overall, our findings showed
60 that skeletal muscle is involved in ZIKV pathogenesis, contributing to a broader
61 understanding of ZIKV infection. Thus, opens new aspects in the investigation of the
62 long-term consequence of early infection.

63

64 **Introduction**

65 Zika virus (ZIKV) is an arbovirus from the *Flaviviridae* family transmitted
66 mainly by *Aedes* mosquitoes. ZIKV disseminated rapidly across the Americas in the last
67 years (1) and although historically this infection caused a self-limited mild febrile
68 condition similar to that induced by other arboviruses, reports of persistent and severe
69 neurological damage started to appear. It is now known that vertical transmission of
70 ZIKV can cause fetal death and congenital defects, such as microcephaly (2) while
71 neuroinflammatory conditions such as Guillain-Barré Syndrome (GBS) and encephalitis
72 have been reported in adult patients (3-6).

73 Several studies have described the molecular mechanisms of the pathogenesis
74 of ZIKV infection, mainly neuroinvasion and the damage on the central nervous system
75 (CNS). It has been demonstrated that ZIKV replicates in human neural progenitor cells
76 and brain organoids, resulting in cell death and cell cycle arrest (7, 8). Both intra-uterine
77 and neonatal ZIKV exposure in mice was shown to compromise neurogenesis and cause
78 severe necrosis in different brain regions, along with persistent viral replication and
79 widespread neuroinflammation (9, 10). Moreover, it was shown that activation of
80 microglial cells and astrocytes associated to viral replication in the brain affects
81 cognitive function and the differentiation of glial progenitors cells impairing brain
82 development (11, 12).

83 Under physiological conditions, the blood brain barrier (BBB) protects the
84 brain from the effects of peripheral infections. However, in some circumstances the
85 integrity of this endothelial barrier can be broken allowing pathogenic agents to reach
86 the brain. It has been hypothesized that viral replication in peripheral tissues could
87 contribute to amplification of viral loads early during ZIKV infection and before the
88 virus invades the CNS (13). ZIKV has been shown to replicate and cross the endothelial
89 barrier without significantly affect its permeability (14, 15). Additionally, it was
90 demonstrated that ZIKV replicates in human peripheral neurons *in vitro* (16). Thus,
91 replication in motors and sensory tissues, in addition to contributes to viral load, could
92 be a route used by ZIKV to access the peripheral nerves and reaches by retrograde
93 axonal-transport some immuno privileged sites such as the brain (17). This is a
94 mechanism known to be involved in infections by other neurotropic viruses including
95 the member of Flaviviridae family, West Nile virus (18-20). Despite the evidence that
96 ZIKV can be detected both during acute and late phases of infection in several

body fluids, eyes, testis and vagina (21). The importance of initial replication sites for the establishment of infection and viral spread remain unknown.

Here we investigated the ability of ZIKV to establish a productive replication in the skeletal muscle. We found that ZIKV replicates in human muscle precursor cells, impairing differentiation and causing cell death. Using mouse models, we showed that ZIKV induce necrotic lesions and inflammation in the muscle of fetuses and newborns by establishing rapid and sustained replication kinetics. Interestingly, ZIKV replication in the muscle temporally precedes the detection of viral RNA in the brain. Taken together, our results indicate that the skeletal muscle is an early site of viral amplification that may contribute to ZIKV reaches neural tissues.

Results

ZIKV replicates in human skeletal muscle progenitor cells, causing cell death

The main extra-neuronal sites of ZIKV replication and the role of peripheral viral replication in the establishment of infection are still poorly understood. In order to evaluate whether muscle is a potential site of ZIKV replication, we infected primary human skeletal muscle myoblast cells (HSMM), both in an undifferentiated stage (myoblast culture) and after cell fusion and differentiation into muscle fibers (myotubes). Temporal quantification of infectious particles in culture media (**Fig 1A**) revealed a rapid increase in ZIKV infectious particles in myoblast cultures, which lasted for at least 48 hours post-infection (hpi). No increase in viral particles from myotubes in culture was observed until 16 hpi, but titers were comparable to those seen in myoblasts at 36 hpi. In agreement with the replication curves, we positive immunostaining against ZIKV E protein (**Figs 1B and 1C**) and ZIKV non-structural 2B protein (NS2B) (**Figs 1D and 1E**) in both myoblasts and myotubes in culture, when analyzed 36 hpi. No

122 staining for either viral protein was observed in mock myoblast (**S1A Fig**) and
123 myotubes (**S1B Fig**) cultures. Quantification of 4G2-positive cells showed a
124 significantly higher number of ZIKV-positive cells in myoblast cultures when compared
125 to myotube cultures at 36 and 48 hpi (**Fig 1H**).

126 Next, we evaluated whether ZIKV replication affects the viability of skeletal
127 muscle cells. When analyzed 48 hpi, we observed that while infection promoted reduced
128 myoblast viability to ~50%, viability of myotubes in cultures exposed to ZIKV was not
129 affected (**Fig 1I**). Furthermore, consistent with these observations, myosin heavy chain
130 (MF20) immunolabeling in mock- and ZIKV-treated myotube cultures showed that
131 ZIKV infection did not alter fiber structure when compared to cells treated with mock
132 (**Figs 1F and 1G**). In addition, quantification of MF20 images showed that the infection
133 did not altered the number of fibers nor the fiber area (**Figs 1J and 1L**), suggesting that
134 ZIKV infection does not interfere with the integrity of the already formed myofiber
135 structures. Taken together, these data suggested that ZIKV is capable of replicating in
136 myogenic cells causing significant cell damage.

137 ***ZIKV infection inhibits myogenesis***

138 Considering our results showing that ZIKV replicates and causes death of muscle
139 progenitor cells, we investigated whether ZIKV interferes with myogenesis by altering
140 the number and integrity of the newly formed fibers. To this end, we subjected human
141 myoblast cultures to fusion and differentiation-inducing medium and infected these
142 cells at an early stage of differentiation (1-day post-differentiation stimuli). Fiber
143 formation was evaluated by MF20 immunolabeling after infection (day 1) and at 5-day
144 post-differentiation stimuli, that cultures reached late stage of differentiation (day 5),
145 and showed a reduction of MF20 positive cells in ZIKV infected culture at day 5

146 comparing to Mock (**Fig 2A**). Quantitative analysis indicated that ZIKV infection
147 promoted a decrease in the average fiber-area and in the amount of differentiated fibers,
148 5 days after differentiation induction (**Figs 2B and 2C**). We also observed a rapid
149 increase in infectious viral particles in culture medium of ZIKV-infected myoblasts
150 under differentiation, and ZIKV replication was maintained for at least 96 hpi (**Fig 2D**).
151 We also observed a reduction in MTT metabolization when compared to mock-treated
152 cultures (**Fig 2E**). These data showed that myoblast differentiation and fiber-occupied
153 area were impacted by viral exposure, suggesting that myogenesis is directly affected by
154 ZIKV infection.

155 *ZIKV replicates and promotes damage in the skeletal muscle in vivo*

156 Since myoblast fusion is critical not only for the correct development of skeletal
157 muscle but also for the adequate function of the developed tissue (22), we investigated
158 the ability of ZIKV to replicate and induce muscle tissue damage during early stages of
159 development *in vivo*. To this end, we first used a mouse model of ZIKV maternal
160 transmission using type-I interferon receptor deficient (IFNAR^{-/-}) pregnant mice in
161 different gestational stages (**Fig 3A**). ZIKV subcutaneous infection at 10.5 days of
162 pregnancy resulted in 100% fetal loss (data not show), whereas a significant reduction
163 in the number of pups born from each dam was observed when infection was conducted
164 at 12.5 days of gestation (**Fig 3B and S2A Fig**). Fetal death following ZIKV infection
165 was further confirmed by the presence of fetal resorption fragments found in the
166 placenta of infected mice (**S2B Fig**). We also observed difference in the pups, which
167 showed low motility and cases of stillbirths after maternal infection in 12.5 days of
168 gestation (**S2A Fig**). The number pups per offspring was not affected when infection
169 was performed at either 14.5 or 18.5 days of gestation. ZIKV RNA was quantified in

170 pups' skeletal muscle from left and right hind legs collected bilaterally at post-natal day
171 0. Although muscular viral titers at birth were higher when infection was performed at
172 earlier stages of pregnancy, viral RNA was detected after infection at all gestational
173 tested (**Fig 3C**). ZIKV RNA was also detected in brains of newborn pups (**Fig 3D**), and
174 viral load was comparable between brain and muscle. Fetal fragments collected from
175 placenta of dams infected at 12.5 days of gestation, however, showed higher viral loads
176 than both brains and muscles of pups analyzed on the day of birth (**Fig S2B**). These data
177 indicate that muscle is a site of ZIKV replication during embryogenesis, sustaining
178 detectable viral loads until the birth of pups.

179 We also investigated ZIKV replication in 3 days-old wild-type (WT) neonatal
180 mice, infected subcutaneously with ZIKV. We observed that ZIKV-infected mice
181 presented a significant reduction in body weight gain when compared to the mock group
182 (**Fig 3E**) and a high mortality rate starting 12 days after ZIKV inoculation (**S2C Fig**).
183 The quantification of ZIKV RNA in the skeletal muscle from hind leg of mice collected
184 bilaterally showed a rapid increase in the viral titers after inoculation (**Fig 3F**), with the
185 replication peak occurring at 2 days post-infection (dpi), and plateauing at least until 6
186 dpi. We also observed an increase of ZIKV titers in spleen at 1 dpi, but in this case the
187 titers decreased to a very low level in the subsequent days (**Fig 3F**). In addition, we did
188 not observe a temporal increase in ZIKV titers in the liver, which showed undetectable
189 values after 4 dpi (**Fig 3F**). These observations indicate that, compared to the rodent
190 spleen and liver, the muscle is an important site of ZIKV amplification amongst
191 peripheral tissues in mice, being able to sustain high viral loads for longer periods.

192 We next investigated whether ZIKV replication in muscle triggers tissue injury
193 and inflammation. Histological analysis demonstrated that ZIKV infection is

194 accompanied by an inflammatory infiltrate in the muscle of newborn pups (P0) after
195 maternal transmission and of neonatal mice 6 dpi (**Figs 4A-4F**). In addition, we
196 observed necrotic areas and alterations on fiber structure. We also found indications of
197 muscle atrophy (**Figs 4B and 4C**). In agreement with the observed morphological
198 alterations, we found increased levels of mRNA of several pro-inflammatory mediators,
199 including TNF, IL-1 β , IL-6 and RANTES, in the skeletal muscle of ZIKV-infected mice
200 compared to mock-injected mice at 6 dpi (**Figs 4G-4J**). No change in mRNA levels of
201 the chemokine MCP-1 (**Fig 4L**) and of the anti-inflammatory cytokines, TFG- β and IL-
202 10 were seen following ZIKV infection compared to mock animals (**S3A and S3B**
203 **Figs**). To investigate whether ZIKV-induced inflammation of muscle tissue leads to an
204 active process of atrophy, we evaluated the expression of Muscle RING Finger 1
205 (MuRF1) and Atrogin-1, both ubiquitin ligases which are associated to degradation of
206 muscle proteins (23). We found an increased expression of both signaling proteins in
207 the muscle of ZIKV-infected mice compared to the control (**Figs 4M and 4N**). These
208 data support that ZIKV replication in muscle tissue promotes inflammation-induced
209 muscular damage.

210 ***ZIKV replicates in muscle prior to reach neural tissue in mice***

211 To investigate the dynamics of ZIKV infection in mice tissues, we compared the time
212 course of virus replication in neural and muscle tissues (**Fig 5A**). Viral amplification in
213 muscle started immediately after virus inoculation (10-fold increase in viral titer is
214 observed at 1 dpi), while an increase in ZIKV RNA levels in dorsal root ganglia (DRG),
215 spinal cord (SC) and brain was detected only at day 4 of infection (ZIKV RNA levels
216 were the same as the viral input until 2 dpi in these tissues, as indicated by dotted line in
217 **Fig 5A**. The absence of virus replication in brain tissue at the early times after infection

is consistent with the preservation of blood brain barrier (BBB) integrity in 3 days-old mice at the moment of ZIKV inoculation (**S3C Fig**), as well as after 2 days of infection (**S3D Fig**). However, ZIKV amplification in the brain became evident at 4 days post-infection, but BBB integrity was not drastically disrupted at this time point (**S3E Fig**). Despite the rapid amplification rates of ZIKV in muscle, the viral load in brain and SC reached levels higher than in muscle after 6 dpi, which was consistent with the known neurotropism of ZIKV.

Replication in DRG is detectable only after 6 days of infection. To confirm that the increase in ZIKV RNA in this tissue corresponds to an active viral replication, we searched for the negative strand of viral RNA (**Fig 5B**). Consistently with the data of pfu equivalent, lower levels of ZIKV RNA negative strand were detected in DRG compared to SC and brain. Interestingly, ZIKV could still be detected in muscle and brain tissue until 16 dpi at the same levels of 6 dpi in the last long-surviving mice (**Fig 5C**). The ZIKV titer was maintained with 2 logs of difference between these tissues. These data indicate that ZIKV establishes a rapid and sustained infection in the muscle tissue, which would contribute to viral amplification and dissemination to neural structures, the main target of replication.

Discussion

ZIKV neurotropism has been extensively characterized due to its potential to induce microcephaly and other birth defects after gestational infection (24, 25). However, the contribution of ZIKV replication in peripheral tissues to pathogenesis is still unexplored. Thus, further investigations concerning the complete range of ZIKV induced lesions, as well as the determinants factors of pathogenesis severity are mandatory to prevent brain damage induced by the infection.

242 Muscular pain is a recurrent symptom associated with ZIKV infection, affecting
243 up to 65% of patients in some outbreaks (26, 27). Skeletal muscle is a widespread body
244 tissue comprised by mature fibers and myogenic precursor cells that are responsible for
245 muscle development and repair (28). Muscle cells have been described as a target for
246 replication of some arboviruses, such as Dengue (DENV) and Chikungunya (CHIKV),
247 playing a significant role in their pathogenesis (29-31). Here we demonstrated that ZIKV
248 replicates and damage cultured human primary muscle cells, and muscle tissue of fetus
249 after maternal transmission and of neonate infected mice. Our data indicates that muscle
250 is a target for ZIKV replication and site of injury. The ZIKV ability to infect and induce
251 muscle damage is consistent with the high frequency of myalgia in patients, including
252 those cases of self-limited disease and with neurological complications (32-34). In
253 addition, it also suggests that an initial muscular replication may be a common step
254 before ZIKV reaches neural structure.

255 Although ZIKV tropism in peripheral tissues was not well characterized yet,
256 clinical studies have shown the viral persistence in several body fluids (21). First's
257 reports evaluating cell permissiveness demonstrated that ZIKV replicates at placental
258 trophoblasts, endothelial cells, human skin fibroblast and neonatal keratinocytes (21, 35,
259 36). ZIKV also replicates and induce morphological alterations in human skin explants
260 (35), that are consistent with skin lesions presented in many ZIKV-infected patients
261 (37). After mosquito inoculation, skin cells (keratinocytes and dendritic cells) are the
262 first target of ZIKV, followed by hematological dissemination. Mosquito or
263 subcutaneous inoculation in non-human primates showed that ZIKV present a broad
264 range tissue distribution with highest load at lymph nodes (38). Differing from DENV
265 infection, *in vitro* and *in vivo* studies indicates that liver, despite susceptibility of some
266 hepatocytes lineages (39), do not sustain high loads of ZIKV amplification in animal

models (38). In agreement with this, we did not find ZIKV amplification in the liver during neonatal infection in mice. Our data suggest that the skeletal muscle is an important peripheral site for ZIKV amplification, mainly when compared with liver and spleen.

Fetal and neonatal muscle tissue is formed by fiber under maturation and muscle precursor cell, which differs according to its proliferative and fusogenic activity (40, 41). Similar to brain, where ZIKV replicates in neural progenitor's cells (42, 43), we demonstrated that muscle precursor cell are the more susceptible to ZIKV than fibers, revealing that the preference for undifferentiated cell is a common feature of ZIKV tropism. In addition, ZIKV replication in neural stem cells also promotes cell death and decreases neurogenesis (44). Our findings suggest that ZIKV-induced cell death of muscle precursor cells may contribute to myogenesis disruption during fetal and neonatal muscle development. We demonstrated that ZIKV replication during muscle cells differentiation impact the number and area of the newly formed fiber. Impaired myogenesis could be related to cell death and with focal muscle atrophy observed in mice muscle at birth after fetal exposure to ZIKV. These data corroborate with clinical findings that showed atrophy of skeletal muscle in a human fetus after ZIKV maternal transmission (45). Further studies to evaluate the relationship between motor function and muscular replication of ZIKV should be addressed.

Muscle body composition after birth, despite present reduced myogenesis, grows very fast due to a high rate of protein synthesis (41, 42). However, a high number of precursor cells are maintained even at adult life, being responsible for muscle repair after injury (46). Thus, muscle precursor cells could be responsible by peripheral ZIKV amplification, even at adult life. In our neonate model, the load of ZIKV in muscle was

291 sustained high until 16 days post-infection, raising the possibility of being a site of viral
292 persistence and inflammation. ZIKV infection also promoted muscle lesions, with
293 inflammatory cell infiltration, together with high levels of TNF, IL-1 β , IL-6 and
294 RANTES. Interestingly, the expressions of muscle degradation proteins were also
295 increased during ZIKV infection in neonate mice. The increase in muscle mass loss
296 could be trigger by several pro-inflammatory cytokines and others inflammatory
297 mediator, such as TNF and IL-1 β (47), that was fouded elevated in muscle during ZIKV
298 infection, and could promote a reduction in muscle hypertrophy during development. In
299 addition, the expression of anti-inflammatory cytokines that are associated with muscle
300 tissue repair, such as TGF and IL-10 (48, 49), were not induced after lesion. Further
301 analysis to evaluate long-term muscle injury and its function after ZIKV infection
302 should be performed to explore this association.

303 Besides to be a peripheral site of ZIKV amplification, temporal analysis of
304 muscular and neural ZIKV replication showed that the virus establishes a rapid and
305 sustained kinetic of amplification in muscle tissue even before the viral replication in
306 the neural tissues in mice. Furthermore, the inability of ZIKV disturb the BBB
307 permeability, after early life infection, reinforces the possibility of viral accesses CNS
308 by peripheral neurons. This is also supported by the detection of ZIKV negative strain
309 in the DRG of neonates (6 dpi), and corroborates with previous studies that
310 demonstrated ZIKV replication in explants and neurons from DRG of ZIKV-infected
311 mice (16, 50). In addition, it was previously demonstrated that ZIKV reaches CNS
312 without disrupt BBB by transcytosis, interfering on its permeability only at late stages
313 of infection (15). However, it does not excludes that ZIKV could use peripheral neural
314 route to access CNS, as already demonstrated to others neurotropic virus (20, 51).

Overall, our findings suggest that maintenance of viral load by muscle replication and inflammation could be an important step in ZIKV pathogenesis. It highlights the importance of investigating the molecular aspects associated with ZIKV-muscle interactions in the initial steps of the infection, dissemination and CNS damage in ZIKV-infected patients. Of note, the control of muscle viral replication could be an important issue for the development of therapeutic strategies to prevent neurological complications after ZIKV infection. Taken together our data contribute to a broader understanding of ZIKV pathogenesis and opens new aspects in the investigation of the long-term consequence of early infection.

Material and Methods

Virus propagation and quantification

Zika virus (ZIKV-BRPE, ref. KX197192), was propagated in C6/36 cell lineage cultured in L-15 medium (Leboviz's Invitrogen) supplemented with 10% of fetal bovine serum (FBS), at 28°C. C6/36 cells were infected in a multiplicity of infection (MOI) of 0.01 in L-15 without serum for 1 hour. After adsorption, medium was removed and infected C6/36 was cultured for 7 days in L-15 supplemented with 5% of serum at 20°C. After this period, culture medium was collected and centrifuged at 2,000 x g for 10 min to remove cell debris. The clarified medium was aliquoted and stored at -80°C. The same procedure was performed in C6/36 uninfected cells, to production of Mock stock. Viral titer of the stock was determined by plaque assay in VERO cells.

VERO cells cultured in D-MEM high glucose (Invitrogen) without serum at 24-well plates at 37°C and 5% of CO₂ atmosphere were infected with ten-fold serial dilutions of ZIKV stock for 1 hour. After this period, medium was replaced by the D-MEM high glucose medium with 1.5% of carboxy-methyl cellulose (CMC-Sigma Co.),

339 1% FBS and 1% penicillin / streptomycin (Invitrogen) and cells cultured for 5 days at
340 37°C and 5% of CO₂ atmosphere. Cells were fixed with a solution of 10%
341 Formaldehyde (Vetec, Sigma Co.) for 30 minutes, and then stained with crystal violet
342 solution (20% Ethanol, 1% Crystal Violet (Sigma Co.) and H₂O). After wash, viral
343 stocks title was calculated as plaque forming units per mL (pfu/mL)

344 *Human primary muscle cells culture, differentiation and infection*

345 HSMM cells (Human Skeletal Muscle Myoblasts) are precursor skeletal muscle cells
346 isolated from the arm or leg of adult healthy donors, were obtained from Lonza cell
347 facility (catalog number CC-2580). These cells were cultured following Lonza
348 specification and medium (SkGMTM medium), at 37°C and CO₂ atmosphere. For the
349 induction of differentiation of myoblast into myotubes, cells were plated with high
350 density and the SkGM medium was supplemented with 2% horse serum (GIBCO® -
351 Life Technologies TM). The culture medium was replaced every two days until the
352 formation of the fibers (about 5-6 days).

353 HSMM myoblast and myotubes were infected with ZIKV using a MOI of
354 5 in SkGM medium without serum during 1 hour. After infection, HSMM were cultured
355 in SkGM medium supplemented with 5% of SFB. Culture medium was temporally
356 collected to determine the amount of ZIKV released during myoblast and myotubes
357 infection by plaque assay. Myoblast and myotubes viability was determined by 3-(4,5-
358 Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT; Life Technologies)
359 metabolization.

360 For the infection during differentiation HSMM was cultured as described above.
361 After 1 day of differentiation stimuli (Day 1), HSMM were mock or ZIKV infected with

362 MOI of 1 and cultured in SKGM differentiation medium until complete 5 days of
363 stimuli (Day 5). Culture medium was temporally collected to determine ZIKV load at
364 medium by plaque assay. Cells were fixed at day 1 and day 5 to immunostaining of
365 fibers formed and cell viability was determined by MTT assay.

366 *Fluorescence microscopy*

367 HSMM cells seeded in 24-well plates were fixed with 4% of formaldehyde in phosphate
368 balanced salt solution (PBS - pH 7.4) at desired time post-infection. Staining for viral
369 proteins was performed using conditioned media of 4G2 hybridoma (anti-flavivirus
370 mouse antibody) at 1:10 dilution. HSMM myofibers were stained using a polyclonal
371 antibody against myosin heavy chain (MF20) at 1:50 dilution. After that, both were
372 stained with a goat anti-mouse Alexa-fluor 488 (Invitrogen) at 1:500 dilution. Cells in
373 each field were visualized with nucleus stained with DAPI (GIBCO® - Life
374 Technologies TM) at 1:10,000 dilution. Images were acquired using an inverted
375 fluorescence microscope (IX81 – Olympus) with magnification of 20X. Images of 4G2
376 positive cells of at least 10 fields were used to determine % of infected HSMM. The cell
377 fusion index in cultured Mock and ZIKV-infected myotubes was determined by
378 quantification of MF20 positive cells in % of total nucleus (DAPI) and fiber area was
379 obtained measuring the fluoresce of MF20 stained normalized by cell number. Image
380 quantification was performed using at least 10 fields using imageJ software (version
381 1.51 j.8).

382 *Mice infection and tissue sample*

383 All experimental procedures performed were in accordance with protocol and standards
384 established by the National Council for Control of Animal Experimentation (CONCEA,

385 Brazil) and approved by the Institutional Animal Care and Use Committee (CEUA),
386 from Federal University of Rio de Janeiro (protocol no. 014/16; CEUA-UFRJ, Rio de
387 Janeiro, Brazil).

388 For mouse model of ZIKV maternal transmission we used 8 week-age type-I
389 interferon receptor deficient (IFNAR^{-/-}) pregnant mice in different gestational stages
390 (10.5, 12.5 and 14.5). Pregnant mice were subcutaneously inoculated with mock or 10⁵
391 pfu of ZIKV in a final volume of 50 µL, and monitored until delivery. The pups were
392 counted; vital signs were observed and photographed at post-natal day 0 (P0). Pups
393 brain and skeletal muscle from left and right hind legs were collected at P0 and fixed in
394 4% formaldehyde to histological or stored at -80 °C to viral quantification analysis.

395 For neonatal mice model, three day-old wide-type (WT) SV129 mice were
396 subcutaneously inoculated with mock or 10⁶pfu of ZIKV in the dorsum in a final
397 volume of 50 µl. Each experimental group was housed individually with the uninfected
398 mothering polypropylene cages, maintained at 25 °C with controlled humidity, under a
399 12 h light/dark cycle with free access to chow and water. Mice were monitored daily
400 and body weight was measured every 2 days. Tissue samples of Mock- and ZIKV-
401 injected mice were collected at different time points and stored at -80 °C until processed
402 to qPCR analysis or fixed in 4% formaldehyde to histological analysis.

403 ***Endothelial barrier integrity analysis***

404 Neonatal mice were subcutaneously inoculated with 50 µL of 1 % Evans blue solution
405 (VETEC) before (3 days-old, moment of infection) and 2, 4 and 12 days after the
406 injection of mock or ZIKV. After 1 h, mice were perfused with PBS, and then the brain
407 and other peripheral tissues (liver, spleen and muscle) were collected to observe Evans
408 blue staining.

409 *Histology*

410 Skeletal muscle from hind legs of mice were collected bilaterally at 6-days post-
411 infection, fixed with 4% of formaldehyde and embedded in paraffin after dehydration.
412 Paraffin-embedded tissue sections of 5 µm were prepared and stained with hematoxylin
413 and eosin (H&E). Images were obtained using optical microscopy with a magnification
414 of 10 X (Olympus BX40), and images were acquired using software Leica Application
415 Suite 3.8 (Leica).

416 *Quantification of ZIKV RNA and proteins expression by qPCR*

417 Tissues were homogenized using a fixed concentration (0.2 mg tissue/µl) in DMEM,
418 and 200 µL of the homogenate were used for RNA extraction with Trizol (Invitrogen)
419 according the manufacturer's instructions. Purity and integrity of RNA were determined
420 by the 260/280 and 260/230 nm absorbance ratios. One µg of isolated RNA was
421 submitted to DNase treatment (Ambion, Thermo Fisher Scientific Inc.) and then
422 reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Thermo
423 Fisher Scientific Inc).

424 For quantification of ZIKV RNA primers for ZIKV were used as described by
425 Lanciotti (2008): forward, 5'-CCGCTGCCCAACACAAG-30; reverse, 5'-
426 CCACTAACGTTCTTTTGCAGACAT-3'; probe, 5'-/56-
427 FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ/-3'
428 (Integrated DNA Technologies). Analyses were carried out on an Applied Biosystems
429 7500 RT-PCR system using the TaqMan Mix (ThermoFisher Scientific Inc) according
430 to manufacturer's instructions. Cycle threshold (Ct) values were used to calculate the
431 equivalence of log₁₀ PFU/µg of total RNA after conversion using a standard-curve with
432 serial 10-fold dilutions of ZIKV stock.

433 To detect negative ZIKV RNA strand in dorsal root ganglion (DRG), RNA was
434 extracted as described above and cDNA was synthesized using 2 pmol of ZIKV 835
435 forward primer instead of random primers. Real time quantitative PCR analysis was
436 performed as described above.

437 Quantification of proteins expression at muscle was performed using the Power
438 SYBR kit (Applied Biosystems; Foster City, CA). Actin was used as an endogenous
439 control. Primer sequences were the following: IL-6 (FW- 5'-
440 TTCTTGGGACTGATGCTGGTG-3'; REV, 5'-CAGAATTGCCATTGCACACTC-3'),
441 MCP-1 (FW, 5'-GTCCCCAGCTCAAGGAGTAT-3'; REV, 5'-
442 CCTACTTCTTCTCTGGGTTG-3'), RANTES (FW, 5'-
443 GTGCCACGTCAAGGAGTAT-3'; REV, 5'-CCTACTTCTTCTCTGGGTTG-3'),
444 TNF (FW, 5'-CCTCACACTCAGATCATCTTCTCA-3'; REV, 5'-
445 TGGTTGTCTTTGAGATCCATGC-3'), IL-1 β (FW, 5'-
446 GTAATGAAAGACGGCACACC-3'; REV, 5'-ATTAGAAACAGTCCAGCCCA -3');
447 Actin (FW, 5'-TGTGACGTTGACATCCGTAAA -3'; REV, 5'-
448 GTACTTGCGCTCAGGAGGAG-3'). MURF1 (FW, 5'-
449 GAGAACCTGGAGAAGCAGCTCAT -3'; REV, 5'-CCGCGGTTGGTCCAGTAG-
450 3'); ATROGIN-1 (FW, 5'-AGAAAAGCGGCACCTTCGT-3'; REV, 5'-
451 CTTGGCTGCAACATCGTAGTT-3').

452

453 *Statistical analyses*

454 Statistical analyses were performed comparing means by two-tailed T-Student's tests
455 using Graph Pad Prism version 7.00 for Windows, Graph Pad Software, La Jolla
456 California USA, www.graphpad.com.

457 **Acknowledgments**

458 This work was supported by grants from Brazilian funding agencies: Fundação de
459 Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ); Conselho Nacional de
460 Desenvolvimento Científico e Tecnológico (CNPq), Agência Financiadora de Inovação
461 e Pesquisa (Finep) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
462 (CAPES), finance Code 001.

463

464 **Authors Contributions**

465 IAM, DGL, CMF, JRC, CPF, CFB and LL designed the experiments. DGL, CMF, LGB,
466 MOLS, SMBA, LDM and RLSN performed the experiments. IAM and DGL analyzed
467 the results. IAM wrote the manuscript. JRC, CPF, CFB and ATDP reviewed and edited
468 the manuscript.

469 **Declaration of interest statement**

470 The authors declare that the research was conducted in the absence of any conflict of
471 interest.

472 **References**

- 473 1. Musso D, Gubler DJ. Zika Virus. *Clinical microbiology reviews*. 2016;29(3):487-524.
- 474 2. Krauer F, Riesen M, Reveiz L, Oladapo OT, Martinez-Vega R, Porgo TV, et al. Zika Virus Infection
475 as a Cause of Congenital Brain Abnormalities and Guillain-Barre Syndrome: Systematic Review. *PLoS*
476 *medicine*. 2017;14(1):e1002203.
- 477 3. Carteaux G, Maquart M, Bedet A, Contou D, Brugieres P, Fourati S, et al. Zika Virus Associated
478 with Meningoencephalitis. *The New England journal of medicine*. 2016;374(16):1595-6.
- 479 4. Nascimento OJM, da Silva IRF. Guillain-Barre syndrome and Zika virus outbreaks. *Current*
480 *opinion in neurology*. 2017;30(5):500-7.
- 481 5. Melo AS, Aguiar RS, Amorim MM, Arruda MB, Melo FO, Ribeiro ST, et al. Congenital Zika Virus
482 Infection: Beyond Neonatal Microcephaly. *JAMA neurology*. 2016;73(12):1407-16.
- 483 6. van der Linden V, Filho EL, Lins OG, van der Linden A, Aragao Mde F, Brainer-Lima AM, et al.
484 Congenital Zika syndrome with arthrogryposis: retrospective case series study. *Bmj*. 2016;354:i3899.
- 485 7. Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, Delvecchio R, et al. Zika virus
486 impairs growth in human neurospheres and brain organoids. *Science*. 2016;352(6287):816-8.

8. Rosa-Fernandes L, Cugola FR, Russo FB, Kawahara R, de Melo Freire CC, Leite PEC, et al. Zika Virus Impairs Neurogenesis and Synaptogenesis Pathways in Human Neural Stem Cells and Neurons. *Frontiers in cellular neuroscience*. 2019;13:64.
9. Nem de Oliveira Souza I, Frost PS, Franca JV, Nascimento-Viana JB, Neris RLS, Freitas L, et al. Acute and chronic neurological consequences of early-life Zika virus infection in mice. *Science translational medicine*. 2018;10(444).
10. Yoon KJ, Song G, Qian X, Pan J, Xu D, Rho HS, et al. Zika-Virus-Encoded NS2A Disrupts Mammalian Cortical Neurogenesis by Degrading Adherens Junction Proteins. *Cell stem cell*. 2017;21(3):349-58 e6.
11. Figueiredo CP, Barros-Aragao FGQ, Neris RLS, Frost PS, Soares C, Souza INO, et al. Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. *Nature communications*. 2019;10(1):3890.
12. Li C, Wang Q, Jiang Y, Ye Q, Xu D, Gao F, et al. Disruption of glial cell development by Zika virus contributes to severe microcephalic newborn mice. *Cell discovery*. 2018;4:43.
13. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. *Neurobiology of disease*. 2010;37(1):13-25.
14. Mustafa YM, Meuren LM, Coelho SVA, de Arruda LB. Pathways Exploited by Flaviviruses to Counteract the Blood-Brain Barrier and Invade the Central Nervous System. *Frontiers in microbiology*. 2019;10:525.
15. Papa MP, Meuren LM, Coelho SVA, Lucas CGO, Mustafa YM, Lemos Matassoli F, et al. Zika Virus Infects, Activates, and Crosses Brain Microvascular Endothelial Cells, without Barrier Disruption. *Frontiers in microbiology*. 2017;8:2557.
16. Oh Y, Zhang F, Wang Y, Lee EM, Choi IY, Lim H, et al. Zika virus directly infects peripheral neurons and induces cell death. *Nature neuroscience*. 2017;20(9):1209-12.
17. Morrison BM. Neuromuscular Diseases. *Seminars in neurology*. 2016;36(5):409-18.
18. Ohka S, Matsuda N, Tohyama K, Oda T, Morikawa M, Kuge S, et al. Receptor (CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome. *Journal of virology*. 2004;78(13):7186-98.
19. MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. *PLoS pathogens*. 2018;14(7):e1007188.
20. Samuel MA, Wang H, Siddharthan V, Morrey JD, Diamond MS. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(43):17140-5.
21. Miner JJ, Diamond MS. Zika Virus Pathogenesis and Tissue Tropism. *Cell host & microbe*. 2017;21(2):134-42.
22. Grounds MD. The need to more precisely define aspects of skeletal muscle regeneration. *The international journal of biochemistry & cell biology*. 2014;56:56-65.
23. Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogen-1. *American journal of physiology Endocrinology and metabolism*. 2014;307(6):E469-84.
24. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*. 2016;47(1):6-7.
25. Wang JN, Ling F. Zika Virus Infection and Microcephaly: Evidence for a Causal Link. *International journal of environmental research and public health*. 2016;13(10).
26. Ng DHL, Ho HJ, Chow A, Wong J, Kyaw WM, Tan A, et al. Correlation of clinical illness with viremia in Zika virus disease during an outbreak in Singapore. *BMC infectious diseases*. 2018;18(1):301.
27. Passos SRL, Borges Dos Santos MA, Cerbino-Neto J, Buonora SN, Souza TML, de Oliveira RVC, et al. Detection of Zika Virus in April 2013 Patient Samples, Rio de Janeiro, Brazil. *Emerging infectious diseases*. 2017;23(12):2120-1.
28. Chal J, Pourquie O. Making muscle: skeletal myogenesis in vivo and in vitro. *Development*. 2017;144(12):2104-22.
29. Warke RV, Becerra A, Zawadzka A, Schmidt DJ, Martin KJ, Giaya K, et al. Efficient dengue virus (DENV) infection of human muscle satellite cells upregulates type I interferon response genes and differentially modulates MHC I expression on bystander and DENV-infected cells. *The Journal of general virology*. 2008;89(Pt 7):1605-15.

30. Lohachanakul J, Phuklia W, Thannagith M, Thongsakulprasert T, Smith DR, Ubol S. Differences in response of primary human myoblasts to infection with recent epidemic strains of Chikungunya virus isolated from patients with and without myalgia. *Journal of medical virology*. 2015;87(5):733-9.
31. Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, Kardon G, et al. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus. *Journal of virology*. 2014;88(5):2414-25.
32. Azeredo EL, Dos Santos FB, Barbosa LS, Souza TMA, Badolato-Correa J, Sanchez-Arcila JC, et al. Clinical and Laboratory Profile of Zika and Dengue Infected Patients: Lessons Learned From the Co-circulation of Dengue, Zika and Chikungunya in Brazil. *PLoS currents*. 2018;10.
33. Duca LM, Beckham JD, Tyler KL, Pastula DM. Zika Virus Disease and Associated Neurologic Complications. *Current infectious disease reports*. 2017;19(1):4.
34. Vieira M, Costa CHN, Linhares ADC, Borba AS, Henriques DF, Silva E, et al. Potential role of dengue virus, chikungunya virus and Zika virus in neurological diseases. *Memorias do Instituto Oswaldo Cruz*. 2018;113(11):e170538.
35. Hamel R, Dejarnac O, Wichit S, Ekcharyawat P, Neyret A, Luplertlop N, et al. Biology of Zika Virus Infection in Human Skin Cells. *Journal of virology*. 2015;89(17):8880-96.
36. Kim JA, Seong RK, Son SW, Shin OS. Insights into ZIKV-Mediated Innate Immune Responses in Human Dermal Fibroblasts and Epidermal Keratinocytes. *The Journal of investigative dermatology*. 2019;139(2):391-9.
37. Paniz-Mondolfi AE, Blohm GM, Hernandez-Perez M, Larrazabal A, Moya D, Marquez M, et al. Cutaneous features of Zika virus infection: a clinicopathological overview. *Clinical and experimental dermatology*. 2019;44(1):13-9.
38. Dudley DM, Newman CM, Lalli J, Stewart LM, Koenig MR, Weiler AM, et al. Infection via mosquito bite alters Zika virus tissue tropism and replication kinetics in rhesus macaques. *Nature communications*. 2017;8(1):2096.
39. Tricot T, Helsen N, Kaptein SJF, Neyts J, Verfaillie CM. Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess the efficacy of potential antivirals. *PloS one*. 2018;13(12):e0209097.
40. Christ B, Brand-Saberi B. Limb muscle development. *The International journal of developmental biology*. 2002;46(7):905-14.
41. Davis TA, Fiorotto ML. Regulation of muscle growth in neonates. *Current opinion in clinical nutrition and metabolic care*. 2009;12(1):78-85.
42. Gokhin DS, Ward SR, Bremner SN, Lieber RL. Quantitative analysis of neonatal skeletal muscle functional improvement in the mouse. *The Journal of experimental biology*. 2008;211(Pt 6):837-43.
43. Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. *Cell stem cell*. 2016;18(5):587-90.
44. Souza BS, Sampaio GL, Pereira CS, Campos GS, Sardi SI, Freitas LA, et al. Zika virus infection induces mitosis abnormalities and apoptotic cell death of human neural progenitor cells. *Scientific reports*. 2016;6:39775.
45. Chimelli L, Melo ASO, Avvad-Portari E, Wiley CA, Camacho AHS, Lopes VS, et al. The spectrum of neuropathological changes associated with congenital Zika virus infection. *Acta neuropathologica*. 2017;133(6):983-99.
46. O'Connor RS, Pavlath GK. Point:Counterpoint: Satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. *Journal of applied physiology*. 2007;103(3):1099-100.
47. Londhe P, Guttridge DC. Inflammation induced loss of skeletal muscle. *Bone*. 2015;80:131-42.
48. Delaney K, Kasprzycka P, Ciemerych MA, Zimowska M. The role of TGF-beta1 during skeletal muscle regeneration. *Cell biology international*. 2017;41(7):706-15.
49. Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. *Journal of immunology*. 2012;189(7):3669-80.
50. Swartwout BK, Zlotnick MG, Saver AE, McKenna CM, Bertke AS. Zika Virus Persistently and Productively Infects Primary Adult Sensory Neurons In Vitro. *Pathogens*. 2017;6(4).
51. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. *Current topics in microbiology and immunology*. 2005;292:45-56.

599 **Figure Captions**

600 **Figure 1. ZIKV replicates and promotes death of human skeletal muscle**
601 **progenitor cells.** Human primary skeletal myoblast and differentiated myotubes culture
602 were infected with ZIKV with a MOI of 5 and temporally assessed. (A) ZIKV released
603 at cultures supernatant at different times post-infection was quantified by plaque assay
604 (n=3-5 each point); (B-G) Immunofluorescence analysis for detection of ZIKV positive
605 myoblast (B and D) and myotubes (C and E) 36 hours post-infection using anti-
606 flavivirus E protein 4G2 and anti-NS2b of ZIKV. White arrows indicate some positive
607 cells; (F-G) detection of fibers at Mock (F) and ZIKV (G) infected myotube culture
608 using anti-myosin heavy chain (MF20) 48 hours post infection; (H) Quantitative
609 analysis of 4G2 positive cells in % of total (Nuclear staining with DAPI) was performed
610 using at least 10 fields of 2 independent experiments using ImageJ software; (I)
611 myoblast (white bars) and myotubes (black bars) viability was determined by MTT
612 reduction 48 hours post ZIKV infection related to Mock of 3 independent experiments
613 in triplicate; (J-k) Quantification of MF20 positive was used to determine cells fusion
614 index (J) and fiber area (k) related to total of cells (nuclear staining with DAPI) at
615 differentiated culture 48 hours post ZIKV infection and mock using at least 10 fields of
616 2 independent experiments using ImageJ software. Data was analyzed using ANOVA
617 (A and H) and Mann-Whitney non-parametric tests (I). *p<0.05

618 **Figure 2. ZIKV infection inhibits myogenesis.** Skeletal muscle progenitor cells were
619 subjected to differentiation into myotubes. At day 1 of differentiation were Mock or
620 ZIKV infected with MOI of 1, then was cultured until day 5 of differentiation. (A) Cells
621 were fixed at day 1 and 5 of differentiation and formed fibers were detected by
622 immunofluorescence using MF20 (red) and cell nucleus was stained with DAPI (blue).
623 (B) Fiber area and (C) fusion index (%) of mock (black bars) and ZIKV infected cell

(white bars) were obtained by fluorescence images analysis of at least 10 fields of tree independent experiments using ImagJ software. **(D)** ZIKV released at culture supernatant at different times post-infection was quantified by plaque assay (n=3, each point). **(E)** Cell Viability was determined by MTT metabolization 96 h post ZIKV infection with MOI of 0.5 and 1; values are expressed as a % of mock group (control). Statistical analysis was performed by two-way ANOVA. ****p<0.0001

Figure 3. ZIKV replicates at mice muscle after maternal transmission and neonatal infection. **(A)** Schematically representation of the period of ZIKV infection at pregnant SVA129 mice (**model 1 – red arrow**) and pups of SV129 mice (**model 2 – blue arrow**). **Model 1** - SVA129 female was Mock or ZIKV infected (10^5 pfu) at different pregnancy period (12.5, 14.5, and 18.5, n=3 each) and pups were analyzed at birth; **(B)** Number of pup per litter after infection at 12.5 of pregnancy; **(C and D)** Muscle and brain were collected at birth after ZIKV inoculation at different pregnancy period of infection (**PPI**). ZIKV RNA at tissue was quantified by qPCR in samples of 3 independent experiments. **Model 2** – 3 days-old WT SV129 mice was mock or ZIKV infected (10^6 pfu) and temporally accompanied. **(E)** Weight gain after infection (n=8); **(F)** muscle, liver and spleen tissues were collected to quantification of ZIKV RNA load by qPCR at different times post infection (n=4-6, each point). N: indicates non-detectable. Statistical analysis was performed by **(I)** unpaired t test and **(E and F)** two-way ANOVA followed of Tukey's multiple comparisons test. *p<0.05, **p<0.01 and ***p<0.001.

Figure 4. ZIKV induces muscle inflammation and damage in pups and neonate infection. SVA129 mice at 12.5 of gestation and 3 days-old WT SV129 mice were Mock or ZIKV infected. Skeletal muscle from hind legs of pups and of neonate were collected bilaterally and fixed at birth or 6 days post-infection, respectively, for

649 histological analysis (**A-F**). Muscle tissues were embedded in paraffin after dehydration
 650 and tissue sections of 5 μ m were prepared and stained with H&E. Scale bar = 100 μ m.
 651 Black arrows areas of inflammation; red arrows indicate atrophy areas; dashed lines
 652 indicated areas of intense lesion. (**G-N**) Skeletal muscle from hind legs of neonates was
 653 collected at 6 days post-infection and the levels of TNF- α , IL-6, MCP-1, IL-1 β ,
 654 RANTES, MURF and Atrogin expression were determined related to Mock group by
 655 qPCR using β -actin expression as endogenous control. Values were plotted as mean $\pm$
 656 Standard Error of Mean (SEM). Statistical analysis was performed using two-sided
 657 Mann-Whitney test. $P \leq 0.05$, $** \leq 0.01$.

658 **Figure 5. ZIKV replicates in muscle prior to reach neural tissue in mice.** (**A**) 3
 659 days-old WT SV129 mice were ZIKV infected and the ZIKV replication kinetic at
 660 muscle, brain, spinal cord (SC) and dorsal root ganglia (DRG) was determined by
 661 qPCR. (**B**) Negative strain amplification was detected by qPCR in neural structures 6
 662 days post-infection and CT values (cycle threshold) were plotted. (**C**) ZIKV load was
 663 detected at late times post-infection in muscle and brain. ZIKV RNA load in **A** and **C**
 664 were plotted as mean $\pm$ standard error (SEM) of ZIKV equivalent of PFU/ μ g of total
 665 RNA.

666

667 **Supporting Information**

668

669 **Supplementary figure 1.** Immunofluorescence staining of ZIKV proteins in mock
 670 myoblast (**A**) and myotubes (**B**) 36 hours post-infection using anti-flavivirus E protein
 671 4G2 and anti-NS2b of ZIKV.

672 **Supplementary figure 2. ZIKV infection during middle gestational stage in mice**
 673 **result fetal death.** Females of IFNAR^{-/-} mice were inoculated with ZIKV or mock on
 674 12.5th gestational day. **(A)** Representative images of litter at born from Mock and
 675 infected female. **(B)** Image of placenta of ZIKV infected female and for viral load at this
 676 samples were quantified by qPCR. **(C)** Survival curve of mock or ZIKV infected WT 3
 677 days-old mice. The survival curve represents two experiments with 7 animals each.

678 **Supplementary figure 3.** Skeletal muscle from hind legs of neonates was collected at 6
 679 days post-infection and the levels of TGF- β **(A)** and IL-10 mRNA **(B)** were determined
 680 related to Mock group by qPCR using β -actin expression as endogenous control. Values
 681 are showed as mean $\pm$ Standard Error of Mean (SEM). Statistical analysis was
 682 performed using two-sided Mann-Whitney test. Blood-brain barrier permeability were
 683 analyzed in 3 days-old WT mice before infection **(B)**, and at different times after Mock
 684 or ZIKV infection **(D-E)** was investigated with subcutaneously inoculation of 1% Evans
 685 blue solution **(EB)** or PBS. After a period of 1h animals were perfused with PBS, brains
 686 and peripheral tissues (spleen, liver and muscle) were removed for visualization.

687

688

B ZIKV infection at 12.5

C

D

E

F

A

B

C

A

Myoblast

B

Myotubes

A **B**

Fetal fragments in the placenta

C Survival of neonate after infection (WT 3-day-old mice)

A **B** **C****WT 3 day-old mice** **D** **E**